Almotriptan in the treatment of acute migraine attacks: A post-marketing study in 899 patients;Almotriptan in der routine-behandlung akuter migräneattacken: Eine post-marketing-studie mit 899 patienten

Nervenheilkunde

Volumn 22, Issue 7, 2003, Pages 365-368

  Diener, Hans Christoph ^a   Landen, H ^b   Stauch, K ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b BAYER AG   (Germany)

Author keywords

Almotriptan; Migraine; Migraine attack

Indexed keywords

ALMOTRIPTAN; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN;

ADULT; AGED; ANALGESIA; ARTICLE; BURN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MIGRAINE; POSTMARKETING SURVEILLANCE; PROPHYLAXIS; RESTLESSNESS; TACHYCARDIA; VERTIGO;

EID: 0141757443     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1626310     Document Type: Article

References (12)

1. Bou J, Domenech T, Puig J, Hereda A, Gras J, Fernandez-Forner D, Beleta J, Palacios JM. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 2000; 410:33-41.
2. Cabarrocas X, Zayas JM, Suris M, on behalf of the Almotriptan Oral Study Group. Equivalent efficacy of oral almotriptan, a new 5-HT1B/D agonist, compared with sumatriptan 100 mg. Headache 1998;38:377-8.
3. Dahlöf C, Tfelt-Hansen P, Massiou H, Fazekas A, and the Almotriptan Study Group. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 2001;57:1811-7.
4. Dahlöf CGH, Dodick D, Dowson AJ, Pascual J. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache 2002;42:99-113.
5. International Headache Society Clinical Trials Subcommitee, Tfelt-Hansen P, Block G. Dahlöf C. Diener HC, Ferrari MD, Goadsby PJ, Guidetti V, Jones B, Lipton RB, Massiou H, Meinert C, Sandrini G, Steiner T, Winter PBO. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia 2000;20: 765-86.
6. Keam SJ, Goa KL, Figitt DP. Almotriptan. A review of its use in migraine. Drugs 2002;62: 387-414.
7. Mathew NT. Almotriptan increases pain-free status in acute migraine patients treated in placebo-controlled trials (abstract). Cephalalgia 2001;21:428.
8. Mathew NT. Oral Almotriptan Study Group. A long-term open-label study of oral almotriptan 12.5mg for the treatment of acute migraine. Headache 2002;42:32-40.
9. Pascual J, Cabarrocas X. Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 2002;42:28-31.
10. Pascual J, Falk R, Docekal R, Prusinski A, Jelencsik J, Cabarrocas X, Segarra X, Luria X, Ferrer P. Tolerability and efficacy of almotriptan in long-term treatment of migraine. European Neurology 2001;5:206-13.
11. Pascual J, Falk RM, Piessens F, Prusinski A, Docekal P, Robert M, Ferrer P, Luria X, Segarra R, Zayas JM. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000;20:588-96.
12. Spierings E, Gomez-Mancilla B, Grosz D, Rowland C, Whaley F, Jirgens K. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 2001;58:944-50.